Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

被引：0

作者：

Afsaneh Alavi

Laura Raffals

机构：

[1] Mayo Clinic,Department of Dermatology

[2] Mayo Clinic,Division of Gastroenterology and Hepatology

来源：

American Journal of Clinical Dermatology | 2022年 / 23卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：593 / 594

页数：1

共 29 条

[1] Author's Reply to Pestana et al. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?"
Alavi, Afsaneh
Raffals, Laura
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (04) : 593 - 594
[2] Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?"
Pestana, Mafalda
Brito Caldeira, Margarida
Cabete, Joana
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (04) : 591 - 592
[3] Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”
Mafalda Pestana
Margarida Brito Caldeira
Joana Cabete
[J]. American Journal of Clinical Dermatology, 2022, 23 : 591 - 592
[4] Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
Tasnim Abdalla
Michelle A. Lowes
Nirmal Kaur
Robert G. Micheletti
A. Hillary Steinhart
Afsaneh Alavi
[J]. American Journal of Clinical Dermatology, 2021, 22 : 139 - 147
[5] Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
Abdalla, Tasnim
Lowes, Michelle A.
Kaur, Nirmal
Micheletti, Robert G.
Steinhart, A. Hillary
Alavi, Afsaneh
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (02) : 139 - 147
[6] Uveitis following the use of tumor necrosis factor α inhibitors:: comment on the article by Lim et al -: Reply
Lim, Lyndell L.
Fraunfelder, Frederick W.
Rosenbaum, James T.
[J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (05): : 1556 - 1557
[7] Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases
Cui, Dejun
Hu, Mei
Zhao, Xun
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1509 - 1509
[8] Response to Raschi E et al. 'Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction'
Gupta, M. A.
Vujcic, B.
Gupta, A. K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : E431 - E432
[9] Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al Reply
Simard, Julia F.
Neovius, Martin
Askling, Johan
[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (06): : 1671 - 1672
[10] Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for Takayasu arteritis: comment on the article by Tian et al Reply
Tian, Xinping
Li, Mengtao
Jiang, Nan
Merkel, Peter A. A.
Zeng, Xiaofeng
[J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 (10) : 1871 - 1873

← 1 2 3 →